Antiphospholipid syndrome (APS) is a thrombo-inflammatory disease propelled by
circulating autoantibodies that recognize cell surface phospholipids and phospholipid …

Abstract Antiphospholipid syndrome (APS), heparin-induced thrombocytopenia, and
paroxysmal nocturnal hemoglobinuria are 3 acquired thrombophilias that carry a high risk of …

Abstract Purpose of Review APS ACTION is an international research network created to
design and conduct large-scale, multicenter research in persistently antiphospholipid …

There is a scarcity of high-quality randomized controlled trials (RCTs) comparing
antithrombotic regimens for secondary prevention of arterial thrombosis (AT) in …

Impact of cardiovascular risk factors in antiphospholipid syndrome: an observational study from
the Spanish national registry Page 1 Clinical and Experimental Rheumatology 2022 Clinical …

Background Patients with antiphospholipid antibodies (aPL) and thromboembolism (TE) are
at risk for recurrent TE. Few studies, however, distinguish patients based on the initial event …

Приведен обзор литературы по механизму развития антифосфолипидного синдрома
(АФС), тактика терапии. Представлены последние рекомендации Европейской …

In this review, we discuss the current evidence on classic and newer oral anticoagulant
therapy, older drugs such as HCQ and statins, and new potential treatment targets in APS …

Antiphospholipid syndrome (APS) is characterized by thrombosis (which may be venous,
arterial, or microvascular) and/or pregnancy morbidity in association with persistently …

Objectives Thrombosis in antiphospholipid syndrome (APS) involves in most cases the
venous circulation. Why in some patients thrombotic APS affects the arterial circulation and …